Acurx Pharmaceuticals (NASDAQ:ACXP) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research report report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock.

Acurx Pharmaceuticals Price Performance

Shares of NASDAQ:ACXP opened at $1.72 on Thursday. Acurx Pharmaceuticals has a 12 month low of $1.52 and a 12 month high of $5.28. The business has a 50-day moving average of $1.95 and a two-hundred day moving average of $2.14. The firm has a market capitalization of $29.05 million, a PE ratio of -1.58 and a beta of -1.73.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.06. During the same quarter in the previous year, the company earned ($0.24) EPS. As a group, research analysts anticipate that Acurx Pharmaceuticals will post -0.89 earnings per share for the current year.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. Geode Capital Management LLC boosted its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 12.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 146,500 shares of the company’s stock after acquiring an additional 16,485 shares during the quarter. Geode Capital Management LLC owned about 0.90% of Acurx Pharmaceuticals worth $278,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.